Peptides for Hair Growth: What GHK-Cu Does and What It Cannot Do

Each follicle cycles through three phases: anagen, the active growth phase, which on the scalp lasts years; catagen, a brief regression of a few weeks; and telogen, a resting phase of a few months at the end of which the hair sheds and a new anagen hair pushes through. On a healthy scalp the large majority of follicles are in anagen at any moment, which is why shedding is steady and unnoticed rather than sudden.

Almost everything called "hair loss" is one of two things: follicles spending less time in anagen and shrinking with each cycle, or an abnormally large number of follicles being pushed into telogen at once. Those are different problems with different fixes.

At the base of each follicle sits the dermal papilla, a cluster of specialized fibroblasts that signals to the surrounding cells when to grow, when to stop and how large a hair to make. It is the control center of the cycle, and it is the structure most of the peptide research is actually about: the Archives of Pharmacal Research 2007 paper on a copper tripeptide, for example, measured proliferation and survival of cultured human dermal papilla cells. When this page says a peptide is described as "supporting the follicle," it nearly always means supporting the dermal papilla and the blood supply feeding it.

A growing follicle has real metabolic demand and is fed by a small vascular bed. Much of the mechanistic case for GHK-Cu, TB-500 and BPC-157 rests on angiogenesis, the growth of new small vessels. That is a tissue-environment argument, and it is not the same as reversing the hormone signal that drives pattern loss.

More than any other complaint on this site, hair is a diagnosis problem before it is a prescription problem. Four things get called "hair loss" and they behave differently.

Androgenetic loss is the follicle-shrinking problem: genetically sensitive follicles respond to dihydrotestosterone with shorter anagen phases and progressively finer hairs. Telogen effluvium is the synchronized-shedding problem: a shock two to four months earlier tipped many follicles into telogen together. Alopecia areata is immune, and traction is mechanical.

If you cannot tell which one you have, resolve that first. A provider who prescribes without asking when the shedding started, whether anything preceded it, and what the pattern looks like is not assessing you.

GHK-Cu is the single-ingredient option. Three amino acids, glycine, histidine and lysine, bound to a copper ion. It occurs naturally in human plasma and declines with age. Its described function is carrying copper to the enzymes that need it, including the ones that cross-link collagen and elastin into structure. The Nature: New Biology 1973 paper that first isolated the tripeptide from human serum is the origin of the literature, and the FEBS Letters 1988 and Journal of Clinical Investigation 1993 papers on collagen synthesis in fibroblasts and connective-tissue accumulation in rat wounds are the core of the repair case.

The hair relevance comes from a second line of work. GHK-Cu is described as supporting the dermal papilla and as promoting the blood-vessel supply around the follicle; the Journal of Cell Biology 1994 paper described copper-binding peptides derived from SPARC stimulating angiogenesis. That is the honest mechanistic case, and it is about the environment around the follicle rather than about blocking the hormone signal that drives pattern loss.

Who it suits: someone whose physician has identified diffuse thinning or scalp quality as the concern, with thyroid, iron and hormonal causes ruled out or separately treated.

RADIANCE pairs GHK-Cu with tesamorelin, a stabilized analogue of growth-hormone-releasing hormone that prompts your pituitary to release a pulse of your own growth hormone. Tesamorelin has the deepest human trial record of anything on this page, but none of it is about hair: the New England Journal of Medicine 2007, Journal of Clinical Endocrinology and Metabolism 2010, JAMA 2014 and Lancet HIV 2019 trials all studied visceral or liver fat in HIV-infected patients with abdominal fat accumulation. Tesamorelin is in RADIANCE for skin and body composition rather than for hair specifically, and it should not be presented to you as a hair peptide.

Who it suits: someone for whom hair is one item on a list that also includes skin quality and body composition, and whose physician considers a growth-hormone-axis peptide appropriate.

GLOW is the hair, skin and soft-tissue combination: GHK-Cu alongside BPC-157 and TB-500 in one vial. All three are described around angiogenesis and cell migration, and TB-500 is the one other peptide on this page with direct follicle research behind it.

BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice. It is in the blend for the repair side: animal research describes it promoting new blood-vessel formation through the VEGF receptor pathway, and the Journal of Applied Physiology 2011 paper described tendon cell survival and migration. There is no BPC-157 research in hair follicles; its main body of work concerns tendon and gut tissue, covered in peptides for healing.

TB-500 is a synthetic fragment related to thymosin beta-4, an abundant intracellular protein that binds actin, the protein that lets cells move. Thymosin beta-4 has been described in follicle research, which is why it appears in this conversation, though that work is preclinical and used the full-length 43-amino-acid protein rather than the shorter TB-500 fragment; the FASEB Journal 2010 paper on the active sites of thymosin beta-4 is the bridge between the two.

Who it suits: someone whose physician sees hair and scalp alongside a repair need, such as skin recovering from a procedure or a soft-tissue issue, and would otherwise be prescribing two vials. It is the most common blend chosen for hair when the concern is not hair alone.

KLOW is GLOW with KPV added. KPV is the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone. It has no hair research of its own; it is in KLOW for the inflammation side. The Gastroenterology 2008 and Inflammatory Bowel Disease 2008 papers describe KPV reducing intestinal inflammation in cell and mouse models, and the Endocrine Reviews 2008 review covers the anti-inflammatory biology of the alpha-MSH tripeptides.

Who it suits: someone with the GLOW picture plus a scalp that is itchy, red or reactive, where the physician wants an anti-inflammatory component in the same vial. An inflamed or scaly scalp still needs a diagnosis first; KPV is not a substitute for a dermatologist looking at it.

ETERNAL is GLOW with epithalon added. Epithalon is a four-amino-acid pineal peptide studied for longevity endpoints rather than hair: the Bulletin of Experimental Biology and Medicine 2003 paper described telomerase activation in human somatic cells, and the Biogerontology 2003 mouse work described effects on markers of ageing. None of the epithalon literature concerns the follicle.

Who it suits: someone using a peptide within a broader anti-ageing plan who wants the GLOW components plus epithalon in one vial, rather than someone whose primary question is hair.

The follicle line of research is old and mostly animal. The Annals of the New York Academy of Sciences 1991 paper from the group that originally commercialized copper peptides reported hair-follicle-stimulating properties of peptide copper complexes in C3H mice. The Journal of Investigative Dermatology 1993 review of agents affecting hair growth in primate and rodent models reported that a copper-binding peptide produced follicular enlargement on the back skin of fuzzy rats, an effect the authors described as similar to that of topical minoxidil in the same model. Both are topical, both are rodent, and neither is GHK-Cu given by injection.

The most-cited human-tissue study is the Archives of Pharmacal Research 2007 paper, which reported that a related copper tripeptide, AHK-Cu, stimulated elongation of human hair follicles ex vivo and proliferation of cultured dermal papilla cells, with a reduction in markers of programmed cell death. Two caveats: the peptide studied was AHK-Cu, an alanine analogue, not GHK-Cu; and ex vivo means follicles kept alive in a dish, not follicles in a scalp.

There is a single randomized, placebo-controlled human study involving the GHK tripeptide and pattern hair loss: the Annals of Dermatology 2016 trial in 45 men, which tested a complex of 5-aminolevulinic acid and GHK, without copper, at two concentrations against placebo for six months and reported an increase in hair count in both treated groups with no significant change in hair length or thickness. It is a small trial of a combination product, the peptide was not copper-bound, and it was not an injection. It tells you something about GHK in follicles and nothing directly about injectable GHK-Cu.

GHK-Cu does have human data; it is just not hair data. The Wound Repair and Regeneration 1994 study reported enhanced healing of ulcers in patients with diabetes treated topically. The Archives of Facial Plastic Surgery 2006 study examined topical copper tripeptide on laser-resurfaced skin. The BioMed Research International 2015 and International Journal of Molecular Sciences 2018 reviews summarize the gene-expression and skin-regeneration work. This is why GHK-Cu is described as having the deepest research base of the repair peptides, and it is also why the honest position on hair is that the follicle-specific research is real but preclinical and topical.

The thymosin beta-4 hair work is the strongest mechanistic story on this page, and it is entirely animal and cell. The FASEB Journal 2004 paper reported that thymosin beta-4 increased hair growth in normal rats and mice and that it acted on bulge-region follicle stem cells, promoting their migration and differentiation and increasing matrix metalloproteinase-2. The Annals of the New York Academy of Sciences 2007 paper extended this across several rat and mouse models, including a transgenic overexpressing mouse, and the Mechanisms of Ageing and Development 2004 paper described the same molecule promoting angiogenesis, wound healing and hair follicle development. The Journal of Cellular and Molecular Medicine 2021 review collected the follicle literature and noted that the molecular mechanism is still not well characterized. No human trial of TB-500 for hair exists.

There are no randomized controlled trials of injectable GHK-Cu, TB-500 or BPC-157 for hair growth in humans, and BPC-157 has no follicle research at all. There is one small randomized trial of a non-copper GHK combination product in men with pattern loss. Tesamorelin's trial evidence concerns visceral fat, not hair. GHK-Cu has the deepest research base of the repair peptides, including human skin studies, and its follicular work is real. It is also mostly cell culture, animal models and topical application. There is no large randomized trial of injectable GHK-Cu for hair growth, and anyone citing one is misreading something.

• It does not establish an effect size for hair. Nobody can tell you how much difference to expect, because that trial has not been run.
• It does not establish a human timeline. Windows described by prescribers are clinical experience, not trial endpoints.
• It does not establish that injectable GHK-Cu reaches the scalp follicle at a concentration comparable to the topical and ex vivo work. That is an assumption in the mechanistic argument.
• It does not establish any effect on the DHT signal that drives androgenetic loss. Nothing in the GHK-Cu literature describes one.

Response varies and no honest prescriber offers a timeline or a result. What a good one offers is a plain account of the evidence and a willingness to say a peptide is the wrong tool.

Compounded peptides are prepared by pharmacies under section 503A of the Federal Food, Drug, and Cosmetic Act. A bulk substance that is not a component of an approved drug and has no USP monograph can only be used if it appears on FDA's 503A bulks list, and while FDA builds that list it publishes three interim categories: Category 1, substances under evaluation; Category 2, substances that raise significant safety concerns; and Category 3, substances nominated without adequate support. FDA's current category document is dated 14 May 2026.

GHK-Cu's status is split by route, and it changed twice this year.

On 15 April 2026 FDA gave notice that "GHK-Cu (except for injectable routes of administration)" would be removed from Category 1, and that "GHK-Cu (for injectable routes of administration)" would be removed from Category 2, in both cases "because the nominations were withdrawn by the nominators." The same notice stated that FDA "intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list."

FDA's 14 May 2026 update then put the non-injectable entry back, after one nominator clarified on 5 May that it had meant to withdraw only the injectable route.

So the accurate description in September 2026 is: GHK-Cu for non-injectable routes is in Category 1, under evaluation; injectable GHK-Cu is not listed in any category because its nomination was withdrawn, and it appears on FDA's page of substances previously in Category 2 whose nominations were withdrawn; and FDA has said it intends to bring GHK-Cu to its advisory committee before the end of February 2027. Pepti's GHK-Cu is dispensed by a state-licensed pharmacy against an individual physician's prescription; whether it is appropriate for you is that physician's decision, and this page will be updated when the committee meets.

These four, which appear in GLOW, KLOW and ETERNAL, followed the same April path out of Category 2 and then went to the committee. FDA's 15 April 2026 notice stated that BPC-157, KPV, Epitalon and "Thymosin Beta-4, Fragment (LKKTETQ), also known as TB-500" would each be removed from Category 2 "because the nominations were withdrawn by the nominators," and that FDA intended to consult the PCAC on BPC-157, KPV and TB-500 on 23 July 2026 and on Epitalon on 24 July 2026. None of the four appears in Category 2 on the current 14 May 2026 document.

The Pharmacy Compounding Advisory Committee met on 23–24 July 2026. FDA's meeting page lists BPC-157, KPV, TB-500 and MOTS-c on 23 July and Emideltide (DSIP), Semax and Epitalon on 24 July, with a briefing document for each, and notes that "advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." As of this writing FDA has not published a final determination on any of the four. The accurate description is: no longer flagged in Category 2, reviewed by the advisory committee in July, awaiting FDA's own decision on the bulks list.

Tesamorelin is different because a branded version is an approved drug. Egrifta (tesamorelin acetate) was approved by FDA on 10 November 2010 for Theratechnologies, and the application was converted to a biologics license in March 2020. The approved indication is narrow: "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy," and the label states it "is not indicated for weight loss management" and is contraindicated in patients with active malignancy. The tesamorelin in RADIANCE is compounded, not the branded product, and compounded tesamorelin is not FDA approved for anything, hair included.

Compounded medications are prepared by licensed pharmacies pursuant to an individual prescription; they are not reviewed and approved by FDA as finished drug products, so no compounded GHK-Cu, GLOW, RADIANCE, KLOW or ETERNAL is FDA approved. What you can verify is the pharmacy's licensure and the batch's certificate of analysis, covered on quality and lab results.

If you are a tested athlete, several components of these blends are on the World Anti-Doping Agency's 2026 Prohibited List, effective 1 January 2026. BPC-157 is named as an example under S0, non-approved substances. "Thymosin-ß4 and its derivatives e.g. TB-500" are listed under S2.3, growth factors and growth factor modulators. Tesamorelin is named under S2.2.4 as a growth hormone-releasing hormone analogue. All are prohibited at all times, in and out of competition. GHK-Cu is not named on the list; if you compete, tell your physician and check with your sport's authority before starting anything.

Nothing visible, and that is expected. A follicle that begins a new anagen phase this month will not push a hair long enough to notice for weeks. What some people report early is scalp-level: less tightness or dryness, or a general skin change if they are on GLOW, RADIANCE, KLOW or ETERNAL, because skin turns over faster than hair grows. Injection-site redness or mild soreness is the usual early complaint.

Where shedding was the problem, this is the window in which prescribers describe it settling, with the caution that telogen effluvium from an event three to six months earlier typically settles in the same window on its own. Any new growth appears first as fine, short hairs along the margins.

If a follicle-level change is going to be noticeable, prescribers generally describe this as the earliest window, because a new anagen hair needs that long to reach a visible length. A photograph taken at the start, in the same light and the same parting, is the only reliable comparison; memory is not.

Treatment is long-term, on 28-day refills, and whether it continues is a decision you make with your physician against the photographs. Hair gained by improving the follicle's environment is generally described as dependent on that environment continuing. How long do peptides take to work covers the general picture.

For hair specifically, most physicians want thyroid function and ferritin at minimum, because those two explain a large share of diffuse shedding and are treatable. At-home blood testing covers thyroid, metabolic and hormone markers without a lab visit. If RADIANCE is under consideration, tesamorelin adds its own questions: the branded label's contraindication in active malignancy is the reason a physician asks about cancer history and glucose before prescribing any growth-hormone-axis peptide.

Injection sites, rotated and watched for anything spreading. Any new scalp symptom, because a peptide does not diagnose an inflammatory or scarring process that was missed. For anyone on high-dose zinc, a conversation about the dose. Photographs at the start and at fixed intervals in the same light.

Detail on the copper-specific cautions is in is GHK-Cu safe.